A trial of lansoprazole in refractory gastric ulcer.

Rensburg, C. Van; Louw, J. A.; Ah, Girdwood; Simjee, A E; Marks, I. N.

doi:10.1111/j.0953-0673.1996.00381.x

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, even after aggressive and prolonged treatment with PPI, not all gastric ulcers heal completely [5,9]. Even after removing noxious environmental agents, poor healing of benign gastric ulcers can still be observed in certain circumstances [5,10]. The pathogenesis of this delayed healing response is not well understood.…”

Section: Introductionmentioning

confidence: 83%

“…The pathogenesis of gastric ulcer involves the interplay between injuries, defense, and repair of the gastric mucosa, as it is constantly exposed to a harmful environment. The chronic nature of gastric ulcers has been described to be associated with the size of the ulcer [1], smoking [2], persistence of Helicobacter pylori infection [3], continued use of nonsteroidal anti‐inflammatory drugs (NSAIDs) [4], and an impaired response to antisecretory agents [5].…”

Section: Introductionmentioning

confidence: 99%

“…Proton pump inhibitors (PPIs) provide better healing effects and fewer relapses than H2RA in managing gastric ulcers [6,8]. However, even after aggressive and prolonged treatment with PPI, not all gastric ulcers heal completely [5,9]. Even after removing noxious environmental agents, poor healing of benign gastric ulcers can still be observed in certain circumstances [5,10].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Delayed healing of gastric ulcer is associated with downregulation of connexin 32 in the gastric mucosa

Wang¹,

Wang²,

Wang³

et al. 2015

Adv in Digestive Medicine

View full text Add to dashboard Cite

Summary Background/Aims Most benign gastric ulcers are healed through suppression of gastric acid by a proton pump inhibitor (PPI). Despite prolonged use of a PPI, some gastric ulcers still do not heal. The primary goal of this study is to investigate the relationship between the expression of connexin 32 (Cx32), a major gap junction protein expressed in the gastric mucosa, and the healing response of gastric ulcers. Methods Patients with endoscopically verified gastric ulcer were treated with a standard dose of PPI for 12 weeks. Histological studies were performed to exclude malignancy. In total, 10 patients having endoscopically verified gastric ulcers with delayed healing at the end of the PPI course were included in this study. The control group consisted of 11 patients with gastric ulcers that healed normally. The expression of Cx32 in the gastric mucosa of the ulcer margin was analyzed by immunoblotting. Results Patients with gastric ulcer showing delayed healing had significantly reduced Cx32 expression in the gastric mucosa compared with the patients in whom the ulcers healed normally (i.e., controls). Age, sex, presence of duodenal ulcers, location and size of gastric ulcer, ulcer staging, Helicobacter pylori infection, use of nonsteroidal anti‐inflammatory drugs (NSAIDs) and aspirin, smoking, and alcohol consumption were similar in both the control and delayed healing groups. H. pylori infection, use of NSAIDs, smoking, and alcohol consumption all had no significant impacts on the expression of Cx32. Age and expression of Cx32 were not correlated. Conclusion Downregulation of Cx32 in the gastric mucosa of the ulcer margin may predict delayed healing in patients with gastric ulcer following acid‐suppression therapy.

show abstract

Section: Introductionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Delayed healing of gastric ulcer is associated with downregulation of connexin 32 in the gastric mucosa

Wang¹,

Wang²,

Wang³

et al. 2015

Adv in Digestive Medicine

View full text Add to dashboard Cite

show abstract

“…The study selection criteria for the second literature search described above were: (i) gastric and duodenal ulcers; (ii) single‐ or double‐blind trial; (iii) healing (famotidine, 40 mg/day) and maintenance (famotidine, 20 mg/day) therapy; (iv) randomized trial; (v) endoscopic examination for ulcer relapse; and (vi) n > 20 for each group. We selected 33 studies, 16 , 18–49 including two Japanese papers, a French paper and a German paper, based on the results of these searches.…”

Section: Methodsmentioning

confidence: 99%

Evaluation of the cost‐effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan

Ikeda

Tamamuro

Hamashima

et al. 2001

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Helicobacter pylori eradication triple therapy with a combination of lansoprazole, amoxicillin and clarithromycin was approved in Japan in September 2000. Aim: To compare the cost‐effectiveness of this eradication therapy with conventional histamine‐2 receptor antagonist therapy in Japan. Methods: We established two Markov models for gastric and duodenal ulcers. The model design was based on the Japanese H. pylori eradication guideline and a specialist’s opinions, and the model inputs were obtained from a literature review. The models predict the direct medical costs, number of disease‐free days and cost per disease‐free day for 5 years. Results: In the gastric ulcer model, the expected total costs of eradication and conventional therapies per patient were ¥169 719 and ¥390 921, respectively; the expected numbers of disease‐free days were 1454 days and 1313 days, respectively. In the duodenal ulcer model, the expected total costs were ¥134 786 and ¥324 689, respectively; the expected numbers of disease‐free days were 1503 days and 1387 days, respectively. The sensitivity analyses showed that the results of the base case analysis were robust. Conclusions: This eradication therapy is less costly and more effective than conventional therapy for the treatment of gastric and duodenal ulcers in a Japanese medical setting.

show abstract

Management of Peptic Ulcer Disease

Duvnjak¹,

Tomašić

2011

Dyspepsia in Clinical Practice

View full text Add to dashboard Cite

A trial of lansoprazole in refractory gastric ulcer.

Abstract: Lansoprazole 30 or 60 mg/day appear equally effective in healing refractory gastric ulcers, while maintenance therapy of 30 mg/day effectively prevented an ulcer relapse.

Cited by 6 publications

References 0 publications

Delayed healing of gastric ulcer is associated with downregulation of connexin 32 in the gastric mucosa

Delayed healing of gastric ulcer is associated with downregulation of connexin 32 in the gastric mucosa

Evaluation of the cost‐effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan

Management of Peptic Ulcer Disease

Contact Info

Product

Resources

About